BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-901 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-901\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07278336-11136@assetmemo.bio
DTSTAMP:20261121T005413Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ABBV-901: Phase 1 readout est. (NCT07278336)
DESCRIPTION:ABBV-901\, phase 1\, Ovarian Cancer.\nStudy: A Study to Assess 
 Adverse Events\, Change in Disease Activity and How Intravenous (IV) ABBV9
 01 Moves Through the Body Alone or in Combination With Other Anticancer Dr
 ugs in Adult Participants With Ovarian Cancer\nEstimated primary completio
 n: December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abb
 v-901#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07278336
URL:https://assetmemo.bio/drug/abbv-901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
